Literature DB >> 9868772

Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolyzing class A beta-lactamase CTX-M-4.

M Gazouli1, N J Legakis, L S Tzouvelekis.   

Abstract

The effect of substitution of asparagine for arginine at position 276 (Ambler's numbering) on the properties of the extended-spectrum beta-lactamase CTX-M-4 was studied. Compared with CTX-M-4, the mutant beta-lactamase CTX-M-4(R276N) conferred lower levels of resistance to cefotaxime, ceftriaxone and aztreonam while the levels of resistance to penicillins and penicillin-inhibitor combinations were similar. Arg-276-->Asn substitution rendered CTX-M-4 slightly less susceptible to inhibition by clavulanate and tazobactam. It also caused a three-fold reduction in the relative rate of hydrolysis of cefotaxime. These results indicate that Arg-276 in CTX-M-type beta-lactamases may be implicated in hydrolysis of oxyimino-beta-lactams; they do not, however, support the hypothesis that Arg-276 is the functional equivalent of Arg-244 found in other class A beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868772     DOI: 10.1111/j.1574-6968.1998.tb13331.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  16 in total

1.  Early dissemination of CTX-M-derived enzymes in South America.

Authors:  Marcela Radice; Pablo Power; Jose Di Conza; Gabriel Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.

Authors:  R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

4.  Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.

Authors:  Akiko Shimizu-Ibuka; Mika Oishi; Shoko Yamada; Yoshikazu Ishii; Kiyoshi Mura; Hiroshi Sakai; Hiroshi Matsuzawa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

5.  Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 beta-lactamase.

Authors:  David C Marciano; Nicholas G Brown; Timothy Palzkill
Journal:  Protein Sci       Date:  2009-10       Impact factor: 6.725

6.  Distant and new mutations in CTX-M-1 beta-lactamase affect cefotaxime hydrolysis.

Authors:  Francisco José Pérez-Llarena; Frédéric Kerff; Olga Abián; Susana Mallo; María Carmen Fernández; Moreno Galleni; Javier Sancho; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

7.  Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.

Authors:  Benoît Doublet; Frédéric Robin; Isabelle Casin; Laëtitia Fabre; Anne Le Fleche; Richard Bonnet; François-Xavier Weill
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Crystal structure of the Mycobacterium fortuitum class A beta-lactamase: structural basis for broad substrate specificity.

Authors:  Eric Sauvage; Eveline Fonzé; Birgit Quinting; Moreno Galleni; Jean-Marie Frère; Paulette Charlier
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

9.  A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil.

Authors:  R Bonnet; J L Sampaio; R Labia; C De Champs; D Sirot; C Chanal; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

10.  Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis.

Authors:  Soichiro Kimura; Masaji Ishiguro; Yoshikazu Ishii; Jimena Alba; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.